MedTrace Logo

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

NCT00236093 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-05-09

No results posted yet for this study

Summary

The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate \[OTFC\]) treatment in children with pain associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who are receiving around the clock (ATC) opioid therapy.

Conditions

Interventions

DRUG

ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])

Sponsors & Collaborators

  • Cephalon

    lead INDUSTRY

Principal Investigators

  • John Messina · Cephalon

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2006-12-31

Countries

  • United States
  • Canada
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00236093 on ClinicalTrials.gov